By Abhishek Vishnoi
MUMBAI (Reuters) - The BSE Sensex and Nifty rose on Tuesday to their highest close in more than a month, with drugmakers getting a shot in the arm after Ranbaxy Laboratories Ltd
Lenders also extended recent gains on rising expectations the Reserve Bank of India would cut rates earlier than expected next year as slumping crude prices are expected to ease inflationary pressures.
Hopes for a loosening of monetary policy were also spurred after Finance Minister Arun Jaitley said he favoured a cut in interest rates, during an interview with a newspaper last week.
Also helping Tuesday's gains were higher global stocks ahead of the U.S. Federal Reserve's two-day meet, where it is expected to reinforce that a softly-softly approach would be taken to raising rates.
Also Read
"Interest rates, inflation, reform cycle... everything is in India's favour but it will come down to the Fed's language on rates for the near-term direction," said Nirakar Pradhan, chief investment officer at Future Generali India Life Insurance.
The Sensex rose 0.48 percent, or 127.92 points, to end at 26,880.82.
The broader Nifty gained 0.45 percent, or 35.90 points, to end at 8,027.60, above the psychologically important 8,000 level.
Both indexes rose for a sixth day in seven and marked their highest close since Sept. 22.
Ranbaxy surged 5.9 percent and was among the leading gainers on the index after swinging to a net profit in the July-September quarter, helped by the exclusive U.S. launch of a generic version of Novartis AG's blood pressure pill Diovan.
Sun Pharmaceutical Industries
Cipla
Lenders rose amid continued hopes of a rate cut and reforms in the sector. State Bank of India closed up 2.3 percent, while ICICI Bank Ltd
Ruchi Soya Industries
However, Jubilant Foodworks
(Editing by Prateek Chatterjee)


